Business Context and Reporting Period
Company: Organon & Co.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Organon is a global healthcare company focused on women's health and general medicines, including biosimilars. The company operates six manufacturing facilities and distributes products in over 140 countries. In 2025, the company shifted its capital allocation priority from growth acquisitions to deleveraging, reducing its dividend payout by 90% and divesting the Jada System in January 2026.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $6.216 billion | $6.403 billion | (3)% |
| Net Income | $187 million | $864 million | (78)% |
| Diluted EPS | $0.72 | $3.33 | (78)% |
| Gross Profit | $3.313 billion | $3.715 billion | (11)% |
| Operating Cash Flow | $700 million | $939 million | (25)% |
| Total Debt (Long-term + Current) | $8.644 billion | $8.880 billion | (3)% |
| Cash and Cash Equivalents | $574 million | $675 million | (15)% |
| Working Capital | $1.96 billion | $1.63 billion | 20% |
Revenue by Portfolio (2025): Women's Health ($1.752 billion), Biosimilars ($691 million), Established Brands ($3.691 billion).
Geographic Mix: 74% of revenue ($4.6 billion) was generated outside the United States.
Material Changes vs. Prior Period
- Revenue Decline: Worldwide sales decreased 3% year-over-year, driven by lower sales of Atozet (due to loss of exclusivity in France, Spain, and Japan), Singulair (price reductions in China/Japan), and Dulera (loss of customer contract). These declines were partially offset by growth in Vtama, Hadlima, Emgality, and Follistim.
- Profitability Impact: Net income dropped significantly due to a $301 million goodwill impairment charge related to the U.S. reporting unit, reflecting lower-than-expected performance of patent-protected products and adverse macroeconomic conditions. Additionally, restructuring costs increased to $95 million (from $31 million in 2024) to drive operational efficiencies.
- Goodwill Impairment: The U.S. reporting unit goodwill was written down to its fair value, resulting in zero excess fair value over carrying amount, making it susceptible to future impairment.
- Dividend Reduction: The quarterly dividend was reduced by 90% in 2025 to preserve cash for debt repayment.
- Leadership Changes: Following an internal investigation into sales practices, the former CEO resigned in October 2025. Joseph Morrissey serves as Interim CEO, and Carrie S. Cox serves as Interim Executive Chair.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
Management is prioritizing debt reduction and deleveraging over M&A. The company expects continued pricing pressure globally, particularly in the U.S. due to the Inflation Reduction Act (IRA) and Most-Favored-Nation (MFN) pricing policies. The company is adapting sales strategies to address changing market conditions and regulatory landscapes.
Key Risks
- Internal Control Weaknesses: The company identified material weaknesses in internal control over financial reporting related to "tone at the top" and communication failures regarding sales practices. An SEC investigation is ongoing.
- Patent Expirations: Nexplanon faces patent expiration in the U.S. in 2027 (rod) and 2030 (applicator), with market exclusivity expiring in other geographies in 2026. Generic competition is expected to impact sales.
- Debt Levels: With approximately $8.6 billion in outstanding indebtedness, the company faces risks related to refinancing and covenant compliance if cash flows do not improve.
- Regulatory and Pricing: Global healthcare reforms, including volume-based procurement in China and price negotiations in the U.S., pose significant risks to margins and revenue.
Contingencies
- Legal Proceedings: The company is involved in product liability litigation (e.g., Fosamax, Nexplanon) and securities litigation regarding capital allocation strategies. A voluntary self-disclosure was made to the SEC regarding wholesaler sales practices.
- Environmental Liabilities: Estimated remediation costs are $14 million for 2026–2030.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of the remediation plan for material weaknesses in internal controls and the outcome of the ongoing SEC investigation.
- Debt Maturity Profile: Review the schedule of debt maturities, noting approximately $3.6 billion of notes maturing in 2028, and assess refinancing risks.
- Nexplanon Exclusivity: Monitor the status of the five-year duration-of-use application and potential generic entry in the U.S. and international markets.
- Goodwill Sensitivity: Assess the sensitivity of the U.S. reporting unit's fair value to changes in revenue growth and discount rate assumptions, given the recent impairment.
- Dividend Sustainability: Evaluate the long-term sustainability of the reduced dividend given the high debt load and capital allocation priorities.